Study of Volrustomig in Women With High Risk Locally Advanced Cervical Cancer (eVOLVE-Cervical)
← catalyst calendarNCT06079671 · readout in 464 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With Gynecologic Oncology Group Foundation, European Network of Gynaecological Oncological Trial Groups (ENGOT).
Phase
Phase 3
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
800estimated
Sites
205
Countries
Brazil, Canada, China +16
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-22 | actual | When the study began enrolling |
| Primary completion | 2027-11-26 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2030-09-30 | estimated | The whole study's end, after follow-up |
| First posted | 2023-10-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Locally Advanced Cervical Cancer
Interventions
- Biological: Volrustomig
- Other: Placebo — also filed as Saline
Primary outcome
what the primary-completion date above is the date OFProgression-free Survival (PFS) based on the investigator assessment in all randomized participants (FAS)
measured Up to approximately 7 years
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed